ANIX - Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
- Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June.
- While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably.
- Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company.
- The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price.
- 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.
For further details see:
Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times